Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm,…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreA recent collaboration between Cytovia Therapeutics and Inserm,…
The National Cancer Institute (NCI) has awarded…
Stand Up To Cancer (SU2C) has awarded the…
Oncopeptides has formally opened…
A nonprofit–industry partnership, led by RCSI University of Medicine…
The navigation platform HealthTree has added a feature…